| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1156: Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy |
|
Medicine details |
|
| Medicine name | osimertinib (Tagrisso®) |
| Formulation | Oral |
| Reference number | 4243 |
| Indication | Maintenance treatment of locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (NSCLC) in adults whose disease has not progressed after platinum-based chemoradiation |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/04/2026 |
| NICE guidance | |